Integra Lifesciences
IART Nasdaq· Health Care Equipment
Last close · Oct 26, 2026
$12.10
KIRA · Stoqly’s AI analyst, in plain words
- Integra Lifesciences had $1.6B of revenue in fiscal 2025, up 1.5% on the year before. Over five years, revenue changed +3.6% a year on average.
- Its operating margin was −30.2%, down 31.9 pts: of every 100 in sales, about −30 is left after running the business.
- Integra Lifesciences lost $517M in fiscal 2025.
- Free cash flow was −$31.1M in fiscal 2025, −1.9% of revenue.
- Integra Lifesciences returned $0.2M to shareholders in fiscal 2025. The diluted share count fell 0.4%.
- Integra Lifesciences owes $463M more than it holds in cash.
Market cap
$951M
P/E
71.2x
Revenue
$1.6B
Net income
−$517M
Free cash flow
−$31.1M
Operating margin
−30.2%
Integra Lifesciences in 30 seconds · fiscal 2025
Are sales growing?
+1.5%
Only a little. Sales grew 1.5% last year.
Does it make a profit?
−31.6%
No. It lost money last year.
Does profit turn into cash?
−1.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
71.2x
One share costs 71.2 times its yearly profit per share. Typical for its sector: 27.9x.
What Integra Lifesciences does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- INTEGRA LIFESCIENCES HOLDINGS CORP
- CIK
- 0000917520
Integra Lifesciences · IART
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.5B | $1.6B | $1.5B | $1.6B | $1.6B |
| Revenue growth | 12.4% | 1.0% | −1.0% | 4.5% | 1.5% |
| Gross margin | 61.2% | 62.3% | 57.4% | 54.8% | 50.9% |
| Operating margin | 12.8% | 15.3% | 7.2% | 1.8% | −30.2% |
| Net income | $169M | $181M | $67.7M | −$6.9M | −$517M |
| Net margin | 11.0% | 11.6% | 4.4% | −0.4% | −31.6% |
| Diluted EPS | $1.98 | $2.16 | $0.84 | −$0.09 | −$6.74 |
| Cash | |||||
| Cash from operations | $312M | $265M | $140M | $129M | $50.4M |
| Capital expenditure | $48.0M | $42.3M | $66.9M | $104M | $81.4M |
| Free cash flow | $264M | $222M | $73.1M | $25.0M | −$31.1M |
| FCF margin | 17.1% | 14.3% | 4.7% | 1.6% | −1.9% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $125M | $275M | $52.5M | $0.2M |
| Share count change | 0.3% | −2.3% | −3.8% | −4.1% | −0.4% |
| Debt and strength | |||||
| Cash and short-term investments | $513M | $457M | $309M | $274M | $264M |
| Debt incl. finance leases | $844M | $775M | $775M | $761M | $727M |
| Shareholders' equity | $1.7B | $1.8B | $1.6B | $1.5B | $1.0B |
| Net debt / EBITDA | 1.3x | 1.1x | 2.8x | 5.3x | — |
| Current ratio | 3.4x | 3.6x | 3.5x | 1.2x | 2.5x |
| Interest coverage | 3.9x | 4.8x | 2.2x | 0.4x | −5.7x |
| Returns and quality | |||||
| Return on capital | 7.9% | 9.8% | 4.5% | 1.1% | −22.0% |
| Return on equity | 10.6% | 10.4% | 4.0% | −0.4% | −39.9% |
| Piotroski F-score | 7 | 8 | 4 | 5 | 5 |
| Altman Z'' | 3.2 | 3.5 | 3.1 | 1.7 | 1.2 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Integra Lifesciences · IART
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Integra Lifesciences IART | $951M | 1.5% | −30.2% | −1.9% | −22.0% | 71.2x | 5 |
| Integer ITGR | $4.3B | 8.0% | 11.9% | 5.7% | 6.6% | 34.7x | 7 |
| Penumbra PEN | $12.9B | 17.5% | 13.5% | 12.5% | 18.8% | 79.9x | 7 |
| LivaNova LIVN | $4.5B | 10.7% | 14.4% | 12.5% | 12.8% | 23.9x | 5 |
| CONMED CNMD | $1.5B | 5.2% | 7.5% | 11.0% | 3.7% | — | 6 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $12.10 a share, the company is worth $951M: 71.2 times its earnings of the last four quarters.
Integra Lifesciences grew sales faster than 0 of its 4 similar companies. Its P/E is higher than 2 of 3.
Source: SEC EDGAR XBRL filings (CIK 0000917520). Data updated October 23, 2026. For information only — not investment advice. Check the original filings before relying on any figure.